ArticleInternational journal of molecular sciences2026
Tissue IL-6/LIF/LIFR and CXCL9 Expression Correlates with High-Risk NBI Patterns and Squamous Cell Carcinoma in Vocal Fold Lesions.
Article in International journal of molecular sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Laryngeal squamous cell carcinoma (SCC) remains a major clinical challenge due to substantial mortality and limited preoperative risk stratification. Narrow-Band Imaging (NBI) enables real-time visualization of mucosal microvasculature, yet the molecular correlates of high-risk NBI phenotypes in vocal fold lesions are incompletely defined. In a prospective cohort of 145 patients with vocal fold lesions, NBI microvascular patterns were graded using the Ni classification and dichotomized using a pre-specified high-risk threshold (Ni ≥ 4 vs. Ni ≤ 3). Histopathology was classified according to WHO 2017. Epithelial expression of IL-6, LIF, LIFR and CXCL9 was quantified by immunohistochemistry using the immunoreactive score (IRS). Associations were tested using non-parametric methods and logistic regression, and diagnostic performance was assessed by ROC analysis. SCC was diagnosed in 63/145 cases. The Ni category showed a strong stepwise association with WHO 2017 histopathological severity. Using Ni ≥ 4, diagnostic performance for SCC was balanced (sensitivity 82.5%, specificity 82.9%; accuracy 82.8%). LIF and LIFR expression decreased with increasing histopathological severity and higher-NBI-risk categories, whereas CXCL9 increased with more suspicious NBI patterns; epithelial IL-6 did not differ across lesion categories. In multivariable logistic regression, Ni ≥ 4 was the strongest independent predictor of SCC (adjusted OR 8.90), while higher LIF (adjusted OR 0.73) and LIFR (adjusted OR 0.78) were independently associated with lower odds of SCC (model AUC 0.943). Multivariable analysis confirmed NBI as the strongest independent predictor of carcinoma, while epithelial LIF and LIFR expression showed inverse associations with histological malignancy and high-risk NBI vascular patterns. LIF/LIFR and CXCL9 show distinct, biologically plausible associations with NBI risk phenotypes, suggesting that selected tissue markers may complement NBI for refined SCC risk stratification.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.